Fibrodysplasia Ossificans Progressiva: what have we achieved and where are we now? follow-up to the 2015 Lorentz Workshop

dc.contributor.authorde Ruiter, Ruben D.
dc.contributor.authorSmilde, Bernard J.
dc.contributor.authorPals, Gerard
dc.contributor.authorBravenboer, Nathalie
dc.contributor.authorKnaus, Petra
dc.contributor.authorSchoenmaker, Ton
dc.contributor.authorBotman, Esmée
dc.contributor.authorSanchez Duffhues, Gonzalo
dc.contributor.authorPacifici, Maurizio
dc.contributor.authorPignolo, Robert J.
dc.contributor.authorShore, Eileen M.
dc.contributor.authorVan Egmond, Marjolein
dc.contributor.authorVan Oosterwyck, Hans
dc.contributor.authorKaplan, Frederick S.
dc.contributor.authorHsiao, Edward C.
dc.contributor.authorYu, Paul B.
dc.contributor.authorBocciardi, Renata
dc.contributor.authorDe Cunto, Carmen Laura
dc.contributor.authorRibeiro Delai, Patricia Longo
dc.contributor.authorVries, Teun J de
dc.contributor.authorHilderbrandt, Susanne
dc.contributor.authorJaspers, Richard T.
dc.contributor.authorKeen, Richard
dc.contributor.authorKoolwijk, Peter
dc.contributor.authorMorhart, Rolf
dc.contributor.authorNetelenbos, Jan C.
dc.contributor.authorRustemeyer, Thomas
dc.contributor.authorScott, Christiaan
dc.contributor.authorStockklausner, Clemens
dc.contributor.authorTen Dijke, Peter
dc.contributor.authorTriffit, James
dc.contributor.authorVentura Pujol, Francesc
dc.contributor.authorRavazzolo, Roberto
dc.contributor.authorMicha, Dimitra
dc.contributor.authorEekhoff, Elisabeth M. W.
dc.date.accessioned2022-02-17T19:27:40Z
dc.date.available2022-02-17T19:27:40Z
dc.date.issued2021-11-10
dc.date.updated2022-02-17T19:27:40Z
dc.description.abstractFibrodysplasia ossificans progressiva (FOP) is an ultra-rare progressive genetic disease effecting one in a million individuals. During their life, patients with FOP progressively develop bone in the soft tissues resulting in increasing immobility and early death. A mutation in the ACVR1 gene was identified as the causative mutation of FOP in 2006. After this, the pathophysiology of FOP has been further elucidated through the efforts of research groups worldwide. In 2015, a workshop was held to gather these groups and discuss the new challenges in FOP research. Here we present an overview and update on these topics.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec719267
dc.identifier.issn1664-2392
dc.identifier.pmid34858325
dc.identifier.urihttps://hdl.handle.net/2445/183270
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fendo.2021.732728
dc.relation.ispartofFrontiers In Endocrinology, 2021, vol. 12
dc.relation.urihttps://doi.org/10.3389/fendo.2021.732728
dc.rightscc-by (c) de Ruiter, Ruben D. et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationMiositis
dc.subject.classificationOssificació
dc.subject.classificationMúsculs
dc.subject.classificationInflamació
dc.subject.otherMyositis
dc.subject.otherOssification
dc.subject.otherMuscles
dc.subject.otherInflammation
dc.titleFibrodysplasia Ossificans Progressiva: what have we achieved and where are we now? follow-up to the 2015 Lorentz Workshop
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
719267.pdf
Mida:
1017.87 KB
Format:
Adobe Portable Document Format